



# Lu-177 Production



Ira Goldman, VP Global Public Policy and Govt Relations

# Disclosures

- Information presented is based on open-source, public information – illustrative and not necessarily comprehensive/complete.
- Personal - NOT official Lantheus information.
- Lantheus concluded Strategic Collaboration and Exclusive License Agreement with Point Biopharma for PNT-002 (Lu-177 PMSA), November 14, 2022.
  - Eli Lilly announced agreement 10/3/2023 to acquire Point Biopharma

# Current Lu-177 Production

Producer	Processing	Reactor(s)	nca/carrier
Eckert & Ziegler	Germany	BR-2 HFR	Yes/No
Isotopia	Israel Canada (AtomVie/CPDC)	BR-2 HFR	Yes/Yes
ITM-ITG (EndolucinBeta®)	Germany Australia - ANSTO	BR-2 OPAL HFR SAFARI FRM-2 ILL (FR)	Yes/No
Isogen/ITM-ITG	Germany	Bruce NPP (Canada)	Yes/No
JSC Isotope	Russia	RIAR, other (Russia)	Yes/Yes
McMasters University	Canada	McMasters RR	No/Yes
Monrol (LuMagic®)	Turkey	BR-2 HFR	Yes/Yes
MURR	USA	MURR	Yes/Yes
Novartis - AAA/IDB	Netherlands Indiana USA (2023?)	HFR INM? (RU)	Yes/Yes
POLATOM (LutaPol)	Poland	Maria	No/Yes
SHINE (IOCB Prague license)	USA	MURR	Yes/No

Additional small-scale production a BRIT (India), PARS (Iran), CMR (Russia), Perkin-Elmer (U.S.) and other locations

# Lu-177 Production Projects

Planned Producer	Partner	Location	Announced
BWXT	Isogen	Canada	7/20/2020
Curium	Monrol (licensee)	Netherlands	1/28/2022
Eckert & Ziegler (\$10M)	Point (supply)	Massachusetts, USA	9/25/2023
IRE/SCK		Belgium Fleurus, Mol/BR-2	2/13/2020 3/4/2022
Isotopia	Seibersdorf Labor	Austria	10/8/2021
Global Morpho Pharma (Framatome minority)	?	?	7/29/2022
Monrol (E35M expansion/new)		Turkey (Gebze)	9/11/2023
Point Biopharma (2023) (Lilly acquisition 10/3/2023)	IRE/SCK (licensee)	Indiana, USA	11/24/2021
SHINE (new facility end 2023)	IOCB Prague	Wisconsin, USA	6/22/2023